Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Cascinu, S ^a   Jelic, S ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; OPIATE; PLATINUM COMPLEX;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GASTROENTEROSTOMY; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE;

EUROPE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; PANCREATIC NEOPLASMS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549123911     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp123     Document Type: Article

References (13)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 67-91.
3. IchiKawa T, Haradome H. Hachiya et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology 1997; 202: 655-662.
4. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
5. Oettle H, Post S, Neuhaus P, Gellert K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007; 297: 267-277.
6. Stocken DD, Buchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381.
7. Huguet F, Andre T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
8. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
9. Cunningham D, Chau I, Stocken C et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 2005; 3 (4 Suppl): 312.
10. Hermann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine versus gemcitabine alone in advanced pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217.
11. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 28: 8-82.
12. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
13. Rykowski JJ, Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: Influence on pain relief. Anesthesiology 2000; 92: 347-354.